Roivant

Vivek Ramaswamy’s brashness made waves in the Republican debate. He did the same in biotech
Vivek Ramaswamy’s brashness made waves in the Republican debate. He did the same in biotech
Stat
Vivek Ramaswamy
2024 Presidential election
biotech
Roivant
Flag link:
Roche in Talks to Buy Stomach Drug from Roivant for $7B: Report
Roche in Talks to Buy Stomach Drug from Roivant for $7B: Report
BioSpace
Roche
Roivant
ulcerative colitis
Crohn's Disease
M&A
Flag link:
Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?
Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?
Motley Fool
Pfizer
Roivant
IBD
RVT-3101
Flag link:
Biotech entrepreneur Vivek Ramaswamy launched his 2024 GOP presidential bid
Biotech entrepreneur Vivek Ramaswamy launched his 2024 GOP presidential bid
Yahoo Finance
Vivek Ramaswamy
Roivant
2024 Presidential election
Flag link:
A year of two halves for US approvals
A year of two halves for US approvals
EP Vantage
FDA
drug approvals
Mounjaro
Eli Lilly
Vabysmo
Roche
Opdualag
Bristol Myers Squibb
Carvykti
JNJ
Vtama
Roivant
Pluvicto
Novartis
Flag link:
10 clinical trials to watch in the first half of 2023
10 clinical trials to watch in the first half of 2023
BioPharma Dive
clinical trials
Alzheimer's disease
obesity
Huntington's disease
M&A
AstraZeneca
Daiichi Sankyo
Nimbus Therapeutics
Takeda
Eli Lilly
Sanofi
Regeneron
Moderna Therapeutics
Gilead Sciences
Pfizer
Roivant
Alnylam
uniQure
Flag link:
Pfizer hands another asset to Roivant
Pfizer hands another asset to Roivant
EP Vantage
Pfizer
Roivant
RVT-3101
PF-06480605
Prometheus Biosciences
Flag link:
Roivant Reduces Pipeline by Several Programs Across Vants
Roivant Reduces Pipeline by Several Programs Across Vants
BioSpace
Roivant
Flag link:
Roivant unveils latest spinout as Pfizer entrusts JAK1/TYK2 to Priovant
Roivant unveils latest spinout as Pfizer entrusts JAK1/TYK2 to Priovant
Endpoints
Roivant
Pfizer
Priovant
spinoffs
Flag link:
FDA approves Roivant drug, the first novel topical plaque psoriasis med in 25 years
FDA approves Roivant drug, the first novel topical plaque psoriasis med in 25 years
MedCity News
Roivant
Vtama
FDA
psoriasis
plaque psoriasis
Flag link:
Roivant's data spinout merges with rival in $7B deal
Roivant's data spinout merges with rival in $7B deal
Endpoints
Roivant
Datavant
M&A
Ciox Health
RWE
data
Flag link:
Immunovant flashes the data that made Roivant want to reacquire it at a potentially hefty premium
Immunovant flashes the data that made Roivant want to reacquire it at a potentially hefty premium
Endpoints
Immunovant
Roivant
myasthenia gravis
thyroid eye disease
Flag link:
Roivant valued at $7B in blank-check merger, bucking SPAC slowdown
Roivant valued at $7B in blank-check merger, bucking SPAC slowdown
BioPharma Dive
Roivant
SPAC
M&A
Flag link:
The SPAC story departs from the script
The SPAC story departs from the script
EP Vantage
Immunovant
Roivant
SPAC
Flag link:
Roivant Sciences founder to step down as CEO
Roivant Sciences founder to step down as CEO
Reuters
Roivant
Phamra CEOs
Vivek Ramaswamy
Flag link:
As Urovant gears up for vibegron FDA decision, the biotech gets snapped up by Sumitovant Biopharma
As Urovant gears up for vibegron FDA decision, the biotech gets snapped up by Sumitovant Biopharma
Fierce Biotech
Urovant
Roivant
FDA
vibegron
overactive bladder
Flag link:
On Heels of the Sale of Five Vants, Roivant Launches New Company Lokavant
On Heels of the Sale of Five Vants, Roivant Launches New Company Lokavant
BioSpace
Roivant
Vivek Ramaswamy
clinical trials
Lokavant
Flag link:
Top Biopharma M&As in 2019
Top Biopharma M&As in 2019
BioSpace
M&A
Bristol-Myers Squibb
Celgene
AbbVie
Allergan
Roche
Spark Therapeutics
Novartis
The Medicines Company
Alkermes
Rodin Therapeutics
Sumitomo Dainippon
Roivant
Flag link:
The Roivant-Sumitomo Deal: $3 Billion, 5 Companies, $550 Million in Loans and an Option on 6 More...
The Roivant-Sumitomo Deal: $3 Billion, 5 Companies, $550 Million in Loans and an Option on 6 More...
BioSpace
M&A
Roivant
Vivek Ramaswamy
Sumitomo Dainippon
Flag link:
Roivant lines up $3B upfront in Sumitomo Dainippon deal
Roivant lines up $3B upfront in Sumitomo Dainippon deal
Fierce Biotech
M&A
Roivant
Sumitomo Dainippon
Flag link:

Pages